Dante Labs is the global leader in whole genome sequencing testing for real people. The impact on human lives of genetic tools can be crucial, which is why Dante Labs wants to democratize genetic information, breaking the rules of a very expensive and long-standing sector, which prevents people from taking care of their health.
Dante Health is the result of a project that aims to bring people closer to the world of genetics, to give them access to the opportunities and tools to consciously monitor their health and make informed decisions about their lives.
This new proposal focuses on specific types of analyzes for the main areas of health care
Performance, Quality and Efficency. Keeping it within everyone's reach.
These three leverage are the base of the Dante Technology and are supported by the most advanced machines available, as the NovaSeq 6000 Sequencing System.
Performance one third over the industry
The amount of data produced by sequencing a biosample is measured in Yield. It is the most reliable measure for genomic analysis and the industry average in terms of Gigabases (Gb) is around 2400-3000 Gb.
Thanks to years of experience and optimizations, Dante Labs performs a Yield average of 3900-4010 Gb, one third better than the rest of the industry.
The percentage of Passing Filter (% PF) is an index that expresses the purity of the signal, depending on the quality of one phases of the sequencing workflow, the cluster creation phase.
The 83% achieved by Dante Labs technology on each run performed, proving also in this case the industry top performance.
The Quality Scores for Next-Generation Sequencing is measured in QC30, a value that reach an industry average of 75%.
Dante Labs NGS technologies have an average performance one-fifth higher than the rest of the industry, with a 90% QC30 and related accuracy results for each step of the sequencing process.
While Dante Health works to offer people the most complete, affordable, and accurate DNA analysis possible, Dante Labs is committed to developing a platform that uses all available experience and data, to push the pharmaceutical and healthcare industry on a cutting-edge level, to offer people personalized treatments and all the advantages of the Precision Medicine.
Immensa is the platform developed by Dante Labs, provided with a proprietary technology and algorithm, made to overcoming the limits of both sides: the risk and time-related ones that the pharmaceutical industry suffers from; and the economic ones and linked to the degree of urgency perceived by individuals.
Chief Executive Officer
Mattia Capulli, PhD
Chief Scientific Officer
Chief Financial Officer
Chief Business Officer
VP Investor Relations
VP Sales, North America
VP Global Head of Business Operations